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Using the concept of inhibition of dipeptidyl peptidase-4 (DPP-4) as a new treatment 
for type 2 diabetes mellitus (T2DM) is based on the inhibition of bioactive peptide 
inactivation process. Most clinical trials on DPP-4 inhibition are based on vildagliptin, 
sitagliptin, saxagliptin, and linagliptin. The drugs may improve glycemic control when 
they are given as a combination with other oral hyperglycemic agents or when they are 
given to patients who received metformin and still had inadequate glycemic control. 
Studies showed that vildagliptin was well-tolerated if it was given as add-on treatment 
to metformin for 24 weeks duration. In addition, vildagliptin showed significant clinical 
improvement proven by the associated decrease in HbA1c and fasting glucose levels. 
Sitagliptin in initial combination therapy with metformin decreased HbA1c level by 2.1% 
after 24 weeks of treatment. It was reported that DPP-4 inhibitor saxagliptin increased 
glycemic control when it was added to metformin. The study included 743 patients 
with an average HbA1c level of 8.0% when they were treated with metformin alone. 
After 24 weeks of treatment, saxagliptin decreased HbA1c level by 0.7%. A multicenter, 
randomized, placebo-controlled, double-blind, parallel-group study examined the efficacy 
and tolerability of linagliptin as treatment adjunctive to metformin in patients T2DM. The 
primary end point was changed in HbA1c from baseline to 24 weeks of treatment. The 
mean adjusted change from baseline in HbA1c in the linagliptin group was 0.49% compared 
with an increase of 0.15% in the placebo group, with 26% and 9% of participants in the 
linagliptin and placebo groups, respectively, achieving an HbA1c 7.0% at 24 weeks. The 
combination of DPP-4 inhibitors and metformin has been shown to be well-tolerated with 
a very low risk of hypoglycemia. Therefore, DPP-4 inhibitors and metformin combination 
is an efficient, safe, and well-tolerated therapy for T2DM.
ABSTRAK
Konsep penghambatan terhadap dipeptidyl peptidase-4 (DPP-4) sebagai obat baru untuk 
diabetes mellitus tipe 2 (DMT2) didasarkan pada penghambatan proses inaktivasi peptida  
bioaktif. Sebagian besar uji klinis penghambat DPP-4 dilakukan menggunakan vildagliptin, 
sitagliptin, saxagliptin, dan linagliptin. Obat tersebut dapat memperbaiki kontrol glikemik 
jika diberikan dalam kombinasi dengan antidiabetes oral lainnya atau jika diberikan 
kepada pasien yang menerima metformin dan kontrol glikemik tidak memadai. Uji klinik 
menunjukkan bahwa vildagliptin dapat ditoleransi dengan baik jika diberikan sebagai 
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obat tambahan pada metformin selama 24 minggu. Selain itu vildagliptin menunjukkan 
perbaikan klinis bermakna yang dibuktikan dengan penurunan HbA1c dan kadar glukosa 
puasa. Sitagliptin sebagai obat tambahan pada metformin menurunkan HbA1c sebesar 
2,1% setelah 24 minggu pengobatan. Dilaporkan bahwa penghambat DPP-4 saxagliptin 
sebagai obat tambahan pada metformin meningkatkan kontrol glikemik. Penelitian 
ini melibatkan 743 pasien dengan HbA1c rata-rata 8,0% saat pasien diobati dengan 
metformin saja. Setelah 24 minggu pengobatan, saxagliptin menurunkan HbA1c sebesar 
0,7%. Uji klinik multisenter, acak terkendali dengan kontrol plasebo, tersamar gada secara 
paralel dilakukan untuk mengkaji efikasi dan tolerabilitas linagliptin sebagai obat tambahan 
metformin pada pasien DMT2. Luaran utama adalah perubahan HbA1c antara sebelum 
dan sesudah pengobatan selama 24 minggu. Rerata penurunan HbA1c dari data awal 
pada kelompok linagliptin adalah 0,49%  dibandingkan dengan kenaikan 0,15% pada 
kelompok plasebo, dengan berturut-turut 26% dan 9% pasien yang diberi linagliptin dan 
plasebo mencapai HbA1c 7,0% setelah 24 minggu. Kombinasi penghambat DPP-4 dan 
metformin terbukti ditoleransi dengan baik dengan risiko hipoglikemia sangat rendah. Oleh 
karena itu, kombinasi penghambat DPP-4 dan metformin efektif, aman dan ditoleransi 
dengan baik untuk terapi DMT2.  
Keywords:  DPP-4 inhibitor – sitagliptin – vildagliptin – saxagliptin – linagliptin – metformin 
- type 2 diabetes mellitus
INTRODUCTION
It has been known that the duration and 
level of hypoglycemia in type 2 diabetes 
mellitus (T2DM) are associated with the 
risk of complications.1 Therefore, glycemic 
control should be achieved for the prevention 
of cardiovascular and microvascular 
complications. The change in lifestyle, 
namely diet control and physical activity, is 
the main aspect in the treatment. However, in 
most patients, pharmacological intervention 
is needed, where metformin is the first line 
treatment. Metformin is a relatively cheap 
agent which mechanism of action is decreasing 
glucose significantly in T2DM patients.2 
Metformin acts mainly through the inhibition 
of glucose degradation process in the liver.3 
Metformin also increases insulin sensitivity 
in the liver and muscle,4 inhibits intestinal 
glucose absorption,5 and increases plasma 
GLP-1 level.6 A study conducted by Bailey 
and Turner3 showed metformin decreased 
HbA1c by 1-1.5%, depends on the HbA1c 
baseline level and patient tolerance, although 
gastrointestinal adverse effects occurred 
quite often at the beginning of the therapy. 
Hypoglycemia and lactic acidosis are seldom 
found in treatment with metformin, but in 
patients with renal insufficiency, adverse 
event monitoring needs to be conducted more 
closely.
Aside from the beneficial effect of 
metformin in improving glycemic control, 
treatment with metformin is usually 
inadequate to achieve metabolic control 
expected. Glycemic control often decreases 
in patients treated with metformin. This is the 
indication for an addition of a second drug. 
Sulphonylurea is the most common agent 
used as a combination, due to its mechanism 
of action in stimulating insulin secretion, that 
supports metformin mechanism of action in 
increasing insulin sensitivity. Other treatment 
combinations include combinations with 
thiazolidinediones and insulin.7 However, 
the combination with sulphonylurea and 
thiazolidinediones also lead to adverse effects. 
Sulphonylurea increases hypoglycemia 
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risk and thiazolidinediones increase body 
weight, cardiovascular risk, and bone 
fractures in women.8,9 This article summarizes 
the experience in using a combination of 
metformin and DPP-4 inhibitors.
DISCUSSION
Dipentidyl peptiase-4 inhibition as the 
target for T2DM treatment
The basis for using DPP-4 inhibitors as 
the treatment for T2DM has been described 
in 1998.10 The study showed that DPP-
4 inhibitors caused an improvement in 
metabolic control by decreasing fasting and 
postprandial glucose level and decreasing 
HbA1c level after 4 weeks of treatment.11 
The improvement in glycemic control by 
DPP-4 inhibitors has been confirmed by 
many studies with other components and now 
several DPP-4 inhibitors are developed. Most 
studies used vildagliptin and sitagliptin which 
are the active oral components that efficiently 
inhibits DPP-4 activity.12 Both components 
inhibit plasma DPP-4 activity for more than 
16 hours after ingestion, therefore both agents 
can be given twice daily. Furthermore, both 
show improvement in glycemic control when 
they are used as combination therapy with 
metformin and thiazolidinediones.13 The 
important feature is that DPP-inhibitors are 
safe and well-tolerated so that they can be 
used as a treatment for T2DM. 
Rationale for combining metformin and 
DPP-inhibitors
Type 2 diabetes mellitus occurs when 
insulin secretion is not comparable with 
the insulin resistance.14 With the increase 
in glucagon level, this will increase glucose 
degradation by the liver and increase the 
fasting glucose level.15 Metformin acts mainly 
by decreasing glucose production from the 
liver and improving insulin sensitivity in the 
liver and muscle, while DPP-4 inhibitors 
act by increasing GLP-1 level so that they 
stimulate insulin secretion and inhibit 
glucagon secretion. Metformin also increases 
the GLP-1 level, that potentially increases 
the synergistic effect with DPP-4 inhibitors. 
Mechanism of metformin in increasing GLP-
1 is not clear; several theories associated it 
with the DPP-4 inhibition,16 several others 
did not find the effect of metformin on 
DPP-4 activity.17 Recent studies showed 
that metformin stimulated GLP-1 secretion 
from the intestine.18 From the aspect of the 
mechanism of action, it is effective to combine 
metformin and DPP-4 inhibitors.
Another important feature is that 
the combination does not change the 
pharmacokinetics, as shown by sitagliptin, 
which furthermore supports the combination 
of both drugs.
Randomized clinical trial vildagliptin as 
add-on therapy to metformin
Several studies reported the use of a 
combination of DPP-inhibitors and metformin. 
The first study was conducted for 52 weeks, 
evaluating vildagliptin 50 mg or placebo 
added to metformin therapy (1.5-3 g per day) 
in patients with mean baseline HbA1c level of 
7.8%.19 Subjects mostly suffered from diabetes 
for 5.5 years and on average were treated with 
metformin for 29 months. The results showed 
that at 12 weeks initial treatment, the HbA1c 
level was decreased by 0.7% in the group 
given vildagliptin combined with metformin 
compared with the group given metformin 
alone. After 12 weeks, subjects were followed 
for 40 weeks. During that time, HbA1c 
increased 0.066%/month in patients on 
metformin therapy compared with an increase 
of 0.013%/month in patients given vildagliptin 
added to metformin. The difference in the 
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change of HbA1c level between groups after 
52 weeks of treatment was 1.1%, showing a 
significant improvement in glycemic control 
with combination therapy of vildagliptin 
and metformin compared to treatment with 
metformin only. This study also showed that 
vildagliptin-metformin combination is safe 
and well-tolerated, and the overall adverse 
events were similar in both groups.
The second study conducted in 416 
patients evaluated the addition of vildagliptin 
50 mg daily or twice daily to metformin 
therapy for the 24-week duration.20 Patients 
in this study had diabetes with a mean 
duration of 6 years and have been treated 
with metformin for an average of 16 months, 
with average metformin dose of 2.1 g daily 
(inclusion criteria was 1.5 g daily). They had 
an average initial HbA1c level of 8.4%. The 
BbA1c level was lowered by 0,5% in patients 
given vildagliptin 50 mg daily and by 0.9% in 
patients given vildagliptin 100 mg daily, both 
in combination with metformin compared 
to the increase of 0.2% in patients given 
placebo as add-on to metformin. The data 
were also analyzed in relation to how many 
patients who had improvement in glycemic 
control or had a failure in glycemic control. 
The analysis showed that in treatment with 
metformin only, 35% of the patients showed 
a failure in glycemic control and 31% did not 
have a significant change in glycemic control. 
In contrast, in patients given vildagliptin 50 
mg combined with metformin, 38% showed 
a significant increase in glycemic control and 
29% had marked an increase in glycemic 
control (defined as a decrease in the HbA1c 
level of more than 1%). The number of adverse 
events was not significantly different between 
groups. The only difference was the decrease 
in gastrointestinal adverse effects in subjects 
given vildagliptin 50 mg in combination with 
metformin (9.6%) compared with that given 
metformin only (18.2%).
In conclusion, large studies showed 
that vildagliptin was well-tolerated if it was 
given as add-on treatment to metformin for 
24 weeks duration and vildagliptin showed 
significant clinical improvement proven by 
the associated decrease in HbA1c and fasting 
glucose levels.
Randomized clinical trial sitagliptin as 
add-on therapy to metformin
The first study on the effect of sitagliptin 
as add-on therapy in patients with inadequate 
glycemic control on metformin monotherapy 
is a 4-week study in 28 patients.21 Patients had 
diabetes for an average duration of 6.6 years, 
with average initial HbA1c level of 7.7% and 
average fasting plasma glucose level of 8.4 
mmol/L. In a long-term study on the effect 
of sitagliptin as add-on therapy to metformin 
in subjects with inadequate glycemic control, 
sitagliptin (100 mg once daily) was added 
to metformin (1.5 g daily) for 24 weeks.22 
A total of 47% of the patients treated with 
sitagliptin in combination with metformin 
achieved target HbA1c of 7%, while it was 
achieved by only 18% of subjects who were 
given metformin only.  The study also showed 
that sitagliptin in combination with metformin 
decreased total cholesterol and triglyceride 
levels slightly, although significantly, while 
HDL-cholesterol level increased slightly. 
Body weight slightly decreased in both 
groups, with no difference between groups. 
The adverse events were also not different 
between groups. Therefore, showed that 
sitagliptin as add-on to metformin efficiently 
decreased HbA1c and fasting glucose 
level, and it was safe and well-tolerated. 
The efficacy and safety of sitagliptin, a highly 
selective DPP-4 inhibitor, when added to 
metformin monotherapy were examined 
in Japanese patients with T2DM. In this 
52-week, an add-on to metformin study, 
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149 patients were randomly assigned to 
receive sitagliptin 50 mg or placebo once 
daily in a double-blind fashion for 12 weeks. 
Thereafter, all patients who completed the 
double-blind period of the study received 
open-label sitagliptin 50 mg once daily for 
40 weeks, with the investigator option of 
increasing sitagliptin to 100 mg once daily 
for patients who met predefined glycemic 
thresholds. After 12 weeks of treatment, 
the mean change from baseline in HbA1 
significantly decreased with sitagliptin relative 
to placebo (between-group difference [95% 
confidence interval] = -0.7% [-0.9 to -0.5] 
P < 0.001). At week 12, the mean changes 
in 2-h post-meal glucose (-2.6 mmol/L 
[-3.5 to -1.7]) and fasting plasma glucose 
(-1.0 mmol/L [-1.3 to -0.6]) also decreased 
significantly with sitagliptin relative to 
placebo (p < 0.001 for both). Significant 
improvements from baseline in glycemic 
control were also observed in the open-label 
period through to week 52. There were no 
differences between treatment groups in the 
incidence of adverse events (AEs), including 
hypoglycemia and predefined gastrointestinal 
AEs (nausea, vomiting, and diarrhea) during 
the double-blind period, with similar findings 
in the open-label period. Over a period of 
52 weeks, the addition of sitagliptin once-
daily to ongoing metformin therapy was 
efficacious and generally well tolerated in 
Japanese patients with T2DM.23
The present study evaluated the efficacy and 
tolerability of sitagliptin 100mg/day added to 
therapy with sulphonylurea and metformin. 
Patients with HbA1c ≥7.5% and ≤10.5% 
while on a sulphonylurea and metformin were 
randomized 1: 1 to sitaglipti 100 mg/day or 
placebo for 24 weeks. At Week 24, patients 
in the placebo group switched to pioglitazone 
30 mg/day and both groups continued 
treatment for another 30 weeks.Of 427 
patients randomized, 339 (79.4%) completed 
the study. At Week 24, significantly greater 
(p < 0.001) mean reductions from baseline 
were seen in the sitagliptin versus placebo 
group for HbA1c (-0.84% vs -0.16%, 
respectively), 2-h post-meal glucose (-2.0 vs 
-0.2 mmol/L, respectively) and fasting plasma 
glucose (-0.7 vs 0.3 mmol/L, respectively). At 
Week 54, improvements in glycemic control 
continued. At Week 24, the incidence of AEs 
was numerically greater with sitagliptin than 
placebo, primarily because of a higher 
incidence of hypoglycemia. At Week 54, the 
incidence of AEs was similar in both groups, 
primarily because of a higher incidence of 
hypoglycemia and edema in the placebo/
pioglitazone group after Week 24. The only 
meaningful change in body weight was an 
increase in the placebo/pioglitazone group at 
Week 54. In this study, sitagliptin 100 mg/day 
was generally well tolerated and provided an 
improvement in glycemic control when added 
to the combination of sulphonylurea 
and metformin in patients with T2DM.24
Randomized control trial saxagliptin as 
add-on therapy to metformin
Recently, it was reported that DPP-
4 inhibitor saxagliptin increased glycemic 
control when it was added to metformin.25 The 
study included 743 patients with an average 
HbA1c level of 8.0% and average fasting 
glucose level of 9.8 mmol/L when they were 
treated with metformin alone. Saxagliptin has 
been added at the dose of 2.5, 5, or 10 mg 
daily and this study also included a placebo 
arm. All patients continued with metformin. 
After 24 weeks of treatment, saxagliptin 
decreased HbA1c level by 0.7% or 0.8% when 
it was adjusted for placebo in the three arms. 
Fasting glucose decreased by 0.9-1.1 mmol/L. 
Similar to other DPP-4 inhibitors, saxagliptin 
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is safe and well-tolerated when it is added to 
metformin.
Saxagliptinas add-on therapy to metformin 
showed significant clinical improvement 
in glycemic control. Average HbA1c level 
decreased by 0.65-1% from the baseline level 
of 7.8-8.4%. Besides, this combination was 
tolerated and safe with similar adverse event 
profile with patients treated with placebo and 
metformin only.
To assess efficacy and safety of 
saxagliptin added to metformin versus 
placebo plus metformin in Asian patients with 
T2DM and inadequate glycemic control on 
metformin alone. Adults (HbA1c 7.0–10.0%, 
on stable metformin ≥1500 mg/day) were 
randomized 1:1 to saxagliptin 5 mg daily 
plus metformin (n = 283) or placebo plus 
metformin (n = 287). The primary endpoint 
was a HbA1c change from baseline to Week 
24. Saxagliptin plus metformin provided 
significant adjusted mean decreases versus 
placebo plus metformin (p ≤ 0.0052) in 
HbA1c (−0.78% versus −0.37%), fasting 
plasma glucose (−1.14 mmol/L versus 
−0.58 mmol/L), and postprandial glucose 
area under the curve from 0 to 180 min 
(−315 mmol min/L versus −160 mmol min/L). 
Significantly more saxagliptin-treated 
patients achieved a therapeutic glycemic 
response (HbA1c < 7.0%) (46.5% versus 
30.5%; p = 0.0001). The proportion of patients 
experiencing adverse events (excluding 
hypoglycemia) was similar for saxagliptin 
plus metformin (42.8%) versus placebo 
plus metformin (40.8%). Hypoglycemic 
events were reported in 1.4% of patients in 
each group. Saxagliptin added to metformin 
significantly improved glycemic control 
and was well tolerated in Asian patients 
with T2DM who had inadequate glycemic 
control with metformin and diet and lifestyle 
modification.26
The aim of other study was to explore 
the efficacy and safety of saxagliptin in a 
large Chinese population with T2DM. In 
all, 1423 T2DM patients from 92 research 
centers, either drug naïve or uncontrolled 
by metformin, were enrolled in this single-
arm cohort study; patients have treated 
with saxagliptin 5 mg once daily for 24 
weeks. The primary efficacy endpoint was the 
change from baseline in HbA1c at 24 weeks 
in the per-protocol analysis set. Secondary 
endpoints included the proportion of patients 
achieving HbA1c <7% and changes from 
baseline in fasting plasma glucose (FPG) 
and 2-h postprandial plasma glucose (PPG) 
concentrations at 24 weeks. Safety endpoints 
included adverse events (AEs) and the 
incidence of hypoglycemia.Among 1210 
patients in the per-protocol analysis set, 
mean HbA1c, FPG and 2-h PPG decreased 
by 1.61 ± 0.04%, 0.55 ± 0.07 mmol/L, and 
2.83  ±  0.27 mmol/L, respectively, at week 
24. The proportion of patients achieving 
HbA1c <7% was 44.1%. No new (previously 
unreported) AEs occurred. The incidence 
of serious AEs and hypoglycemia was low 
(1.8% and 1.2%, respectively). There were no 
significant differences in efficacy endpoints 
in subgroup analyses by age, creatinine 
clearance, body mass index, or treatment 
background. In elderly patients (≥65 years) 
and those with mild renal impairment (50 
< CCr ≤ 80 mL/min), the incidence of AEs was 
similar to that of the entire study population. 
Saxagliptin significantly improved glycemic 
control and was well tolerated in Chinese 
T2DM patients, including the elderly and 
patients with mild renal impairment.27,28
A randomized controlled clinical trial 
conducted to assess efficacy and safety of 
saxagliptin added to metformin versus placebo 
plus metformin in Asian patients with T2DM 
and inadequate glycemic control on metformin 
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alone. Adults (HbA1c 7.0–10.0%, on stable 
metformin 1500 mg/day) were randomized 
1:1 to saxagliptin 5 mg daily plus metformin 
(n = 283) or placebo plus metformin (n = 287). 
The primary endpoint was a HbA1c change 
from baseline to Week 24. Saxagliptin plus 
metformin provided significant adjusted mean 
decreases versus placebo plus metformin ( 
p=0.0052) in HbA1c (0.78% versus 0.37%), 
fasting plasma glucose (1.14 mmol/L versus 
0.58 mmol/L), and postprandial glucose area 
under the curve from 0 to 180 min (315 mmol 
min/L versus 160 mmol min/L). Significantly 
more saxagliptin-treated patients achieved 
a therapeutic glycemic response (HbA1c < 
7.0%) (46.5% versus 30.5%; p = 0.0001). 
The proportion of patients experiencing 
AEs (excluding hypoglycemia) was similar 
for saxagliptin plus metformin (42.8%) 
versus placebo plus metformin (40.8%). 
Hypoglycemic events were reported in 1.4% 
of patients in each group. Saxagliptin added 
to metformin significantly improved glycemic 
control and was well tolerated in Asian 
patients with T2DM who had inadequate 
glycemic control with metformin and diet and 
lifestyle modification.
Randomized clinical trial linagliptin as 
add-on therapy to metformin
A multicenter, randomized, placebo-
controlled, double-blind, parallel-group 
study examined the efficacy and tolerability 
of linagliptin as treatment adjunctive to 
metformin in patients T2DM. Eligible 
participants were aged 18 to 80 years (mean, 
56.5 years) with a BMI of 40 kg/m2 (mean 
baseline BMI, 29.9 kg/m2) and were receiving 
metformin at a dosage of 1500 mg/day (or 
maximum tolerated dose) with or without 
an additional oral antidiabetic (OAD) other 
than a thiazolidinedione. Eligible participants 
receiving metformin monotherapy had a 
baseline HbA1c of 7.0% to 10.0%; in those 
taking metformin plus an OAD, the HbA1c 
range for eligibility was 6.5% to 9.0%. In 
participants receiving an OAD in addition to 
metformin at screening, the additional OAD 
was discontinued, and metformin 1500 mg/
day was continued throughout a 6-week 
washout period prior to randomization. All 
participants completed a 2-week placebo run-
in phase before random assignment to either 
linagliptin 5 mg/day (n=524) or placebo 
(n=177). All participants were required to have 
an HbA1c of 7.0 to 10.0% at randomization. 
The primary end point was changed in HbA1c 
from baseline to 24 weeks of treatment. The 
mean adjusted change from baseline in HbA1c 
in the linagliptin group was 0.49% compared 
with an increase of 0.15% in the placebo 
group (treatment difference =0.64%; 95% 
CI=0.78 to 0.50; p=0.0001), with 26% and 9% 
of participants in the linagliptin and placebo 
groups, respectively, achieving an HbA1c 
7.0% at 24 weeks. Linagliptin treatment was 
associated with significant decreases from 
baseline in FPG (10.6 mg/dL vs 10.5 mg/
dL; p=0.0001) and 2-hour PPG (48.6 mg/
dL vs 18 mg/dL; p=0.0001) compared with 
placebo. Neither treatment group realized 
a statistically significant decrease in mean 
weight (changes from baseline, 0.4 kg and 0.5 
kg with linagliptin and placebo).29
To evaluate the efficacy/safety of DPP-
4 inhibitor, linagliptin, in subjects with 
insufficiently controlled T2DM, and factors 
influencing treatment response. Pooled 
analysis of data from 2258 subjects in three 
24-week phase III, randomized, placebo-
controlled, parallel-group studies, who 
received oral linagliptin (5 mg/day) or placebo 
as monotherapy, added-on to metformin, or 
added-on to metformin plus a sulphonylurea 
was performed. Among 388 subjects with 
HbA1c ≥9.0%, adjusted mean baseline HbA1c 
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(9.4% both groups) declined to 8.3% in 
linagliptin group and 9.1% in the placebo group 
at 24 weeks (p=0.0001) and adjusted mean 
change from baseline was 1.2% (vs. 0.4%, 
placebo). Linagliptin significantly lowered 
fasting plasma glucose levels vs. placebo (1.6 
mmol/L vs. 0.4 mmol/L); treatment difference, 
1.1 mmol/L (95% CI= −1.7 - −0.5). Treatment 
and washout of previous OAD were the only 
factors to independently affect HbA1c change 
at week 24. Adverse event rates were similar 
for linagliptin (61.9%) and placebo (62.7%). 
Hypoglycemia was rare with linagliptin add-
on to metformin (≤1%) and increased when 
linagliptin was added to metformin plus 
sulphonylurea (linagliptin, 17.9% vs. placebo, 
8.3%). Linagliptin was an effective, well-
tolerated treatment in subjects with T2DM 
and insufficient glycemic control, as added-on 
to metformin/metformin plus sulphonylurea.30
Meta-analysis of DPP-4 inhibitors as add-
on to metformin
Meta-analysis was performed to provide 
an update on the efficacy and safety of DPP-
4 inhibitors and metformin as combination 
therapy in patients with T2DM. Meta-analysis 
was performed to provide an update on 
the efficacy and safety of DPP-4 inhibitors 
and metformin as combination therapy 
in patients with T2DM. They were RCTs 
comparing DPP-4 inhibitors (i.e alogliptin, 
dutogliptin, linagliptin, saxagliptin, sitagliptin, 
vildagliptin) plus metformin as combination 
therapy, duration of treatment was ≥12 weeks 
and reported data on HbA1c change, FPG 
change, weight change,  hypoglycaemia or 
gastrointestinal AEs. A total of eight RCTs 
were included. Compared with metformin 
monotherapy, DPP-4 inhibitors plus metformin 
as combination therapy was associated with 
higher reduction in HbA1c level (MD = −0.49; 
95% CI =−0.57 -  −0.40; p = 0.00001), higher 
reduction in FPG level (MD = −0.80; 95% CI 
=−0.87 -  −0.74;  p = 0.00001), lower weight 
loss (MD = 0.44; 95% CI= 0.22 - 0.67; p = 
0.0001);  nor the higher risk of hypoglycaemia 
(RR = 1.04; 95% CI= 0.72 - 1.50;  p = 0.82), 
nor the prolonged risk of gastrointestinal AEs 
(RR = 0.98; 95% CI= 0.88 - 1.10; p = 0.77). 
Dipeptidyl peptidase-4 inhibitors, which are 
safe and effective in controlling the blood 
glucose. It could be a credible alternative for 
T2DM patients who, for some reason, cannot 
use metformin.31
CONCLUSION
Dipeptidyl peptidase-4 inhibitors have 
been proven to be antidiabetic when they 
are given in combination with metformin. 
This novel strategy in treating T2DM is 
expected to increase the future value in T2DM 
treatment. Overall experience shows that this 
novel strategy is efficient, well-tolerated, 
and safe with minimal risk for hypoglycemic 
events. Furthermore, the combination of 
DPP-4 inhibitors and metformin is safe and 
well-tolerated. Therefore, the indication for 
treatment with DPP-inhibitors is as add-
on therapy to metformin in T2DM patients 
uncontrolled with metformin. 
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